Effects of metformin and leuprolide acetate on insulin resistance and testosterone levels in nondiabetic postmenopausal women: a randomized, placebo-controlled trial

What Was Tested

This randomized controlled trial paper looks at Leuprolide in the context of insulin resistance, prediabetes & type 2 diabetes.

Who Took Part

PubMed indexes the participants as middle-aged adults and older adults, women only.

Thirty-five postmenopausal women aged 50-79 years with insulin resistance and higher T levels.

Subjects were randomized to metformin plus leuprolide acetate (LA) placebo, LA plus metformin placebo, or LA placebo plus metformin placebo in a 1:1:1 fashion during a 12-week period.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

The participants were allocated by chance, so the Leuprolide group and the comparison group should start out alike.

As a double-blind Leuprolide study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Leuprolide could be set against what happens without it.

The methods mention a period of 12 weeks.

Clinical and Translational Research Center of a university hospital.

What Was Measured

PubMed files the paper under topics including Fertility Agents, Female, Follicle Stimulating Hormone, Hypoglycemic Agents, Insulin Resistance, Leuprolide, Longitudinal Studies and Luteinizing Hormone.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Leuprolide in people with insulin resistance, prediabetes & type 2 diabetes over 12 weeks.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2010 (Fertility and sterility), a journal based in United States.

More context: the Leuprolide compound page, Insulin resistance, prediabetes & type 2 diabetes research.